Literature DB >> 18025193

Alloimmunity to human endothelial cells derived from cord blood progenitors.

Yajaira Suárez1, Benjamin R Shepherd, Deepak A Rao, Jordan S Pober.   

Abstract

There is considerable interest in exploiting circulating endothelial progenitor cells (EPCs) for therapeutic organ repair. Such cells may be differentiated into endothelial cells (ECs) in vitro and then expanded for use in tissue engineering. Vessel-derived ECs are variably immunogenic, depending upon tissue source, and it is unknown whether ECs derived from cord blood EPCs are able to initiate an allogeneic response. In this study, we compare the phenotype and alloantigenicity of human cord blood progenitor cell-derived ECs with HUVECs isolated from the same donors. Human cord blood progenitor cell-derived ECs are very similar to HUVECs in the expression of proteins relevant for alloimmunity, including MHC molecules, costimulators, adhesion molecules, cytokines, chemokines, and IDO, and in their ability to initiate allogeneic CD4(+) and CD8(+) memory T cell responses in vitro and in vivo. These findings have significant implications for the use of cord blood EPCs in regenerative medicine or tissue engineering.

Entities:  

Mesh:

Year:  2007        PMID: 18025193     DOI: 10.4049/jimmunol.179.11.7488

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress.

Authors:  Melissa A Brown; Charles S Wallace; Mathew Angelos; George A Truskey
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

2.  Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis.

Authors:  Yajaira Suárez; Carlos Fernández-Hernando; Jun Yu; Scott A Gerber; Kenneth D Harrison; Jordan S Pober; M Luisa Iruela-Arispe; Matthias Merkenschlager; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

3.  Blocking MHC class II on human endothelium mitigates acute rejection.

Authors:  Parwiz Abrahimi; Lingfeng Qin; William G Chang; Alfred L M Bothwell; George Tellides; W Mark Saltzman; Jordan S Pober
Journal:  JCI Insight       Date:  2016-01-21

4.  MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Luiz O F Penalva; Devraj Sandhu; Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

5.  Cord blood-circulating endothelial progenitors for treatment of vascular diseases.

Authors:  M Lavergne; V Vanneaux; C Delmau; E Gluckman; I Rodde-Astier; J Larghero; G Uzan
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 6.  Participation of blood vessel cells in human adaptive immune responses.

Authors:  Jordan S Pober; George Tellides
Journal:  Trends Immunol       Date:  2011-10-24       Impact factor: 16.687

7.  Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9.

Authors:  Parwiz Abrahimi; William G Chang; Martin S Kluger; Yibing Qyang; George Tellides; W Mark Saltzman; Jordan S Pober
Journal:  Circ Res       Date:  2015-05-04       Impact factor: 17.367

8.  Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization.

Authors:  Steven M Jay; Benjamin R Shepherd; Jillian W Andrejecsk; Themis R Kyriakides; Jordan S Pober; W Mark Saltzman
Journal:  Biomaterials       Date:  2010-01-27       Impact factor: 12.479

Review 9.  Diabetes-associated macrovascular complications: cell-based therapy a new tool?

Authors:  Maddalena Gili; Alberto Orsello; Sara Gallo; Maria Felice Brizzi
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

10.  Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules.

Authors:  Alexis Morice; Béatrice Charreau; Bérangère Neveu; Sophie Brouard; Jean-Paul Soulillou; Marc Bonneville; Elisabeth Houssaint; Nicolas Degauque
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.